28.04.2023 • NewsSiegfriedR&Ddrug substance

Siegfried Breaks Ground for Global R&D Center

Swiss-based, globally oriented CDMO Siegfried has broken ground or its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland, which the company describes as a “key pillar” in its related network.

From left: Sophia Dini (State Council Delegate for Economy and Innovation),...
From left: Sophia Dini (State Council Delegate for Economy and Innovation), Beat Rieder (Council of State VS, Die Mitte), Valerie Santacrocce-Tachini (President of the municipality Evionnaz), Wolfgang Wienand (CEO Siegfried), Marcel Signer (Site Head Siegfried Evionnaz), Irene Wosgien (COO DS Siegfried), Jürgen Roos (CSO Siegfried), Andreas Casutt (VRP Siegfried) © Siegfried

The new center, costing as much as 25 million Swiss francs to build, is set to begin operations in 2024 with 100 “highly skilled specialists.” Together with the research center at its home base in zofingen, Siegfried said the new facility will “significantly increase R&D capacity to drive future growth.“

With its advanced chemical and analytical facilities and state-of-the-art laboratories, the center will offer chemical process R&D and analytical development services for the entire drug substances network. CEO Wolfgang Wienand said the facility center will not only strengthen its site in Evionnaz, but also its global network.  

Author: Dede Williams, Freelance Journalist

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.